AMRN Makes Peace With Apotex, IDYA Cuts Deal With GSK, SLRX On Watch, NBIX, TAK Ink $2Bln Pact

Today’s Daily Dose brings you news about Amarin’s settlement agreement with Apotex; Annovis Bio’s progress in its Alzheimer’s drug development program; IDEAYA’s deal with GlaxoSmithKline; promising results of Lilly’s monarchE study in breast cancer; Neurocrine Biosciences and Takeda’s $2 billion-plus collaboration; and Salarius’ big event for today. Read on… 1. Amarin Makes Peace With Apotex Amarin Corporation plc (AMRN) has […]

» Read more

UK ministers in talks to create air bridges with ‘core’ European nations

Ministers are in talks to create “air bridges” with a number of “core” European countries including Spain, Italy, Greece, France, Turkey and Croatia to let holidaymakers go abroad this summer without having to quarantine on their return. Austria and Germany are also among the countries officials are considering, the Guardian understands. There are hopes an announcement will be made before […]

» Read more

Lyft Settles Disabled Discrimination Lawsuit

Lyft has agreed to settle allegations that it violated federal law when some of its drivers refused to give rides to people using foldable wheelchairs or walkers, the U.S. Department of Justice said in a statement. As part of the settlement, Lyft agreed to pay damages ranging from $4,000 to $30,000 to four complainants with disabilities and a $40,000 civil […]

» Read more

U.S. Homebuilder Confidence Improves Much More Than Expected In June

Suggesting housing is well positioned to lead a post-pandemic economic recovery, the National Association of Home Builders released a report on Tuesday showing a continued rebound in U.S. homebuilder confidence in the month of June. The report said the NAHB/Wells Fargo Housing Market Index spiked to 58 in June from 37 in May, continuing to rebound from the nearly eight-year […]

» Read more

BoJ Holds Monetary Policy Steady, Boosts Covid-19 Lending Program

Japan’s central bank kept its key interest rate unchanged and expanded the size of the coronavirus lending program on Tuesday to support the coronavirus pandemic-hit economy. The Policy Board of the Bank of Japan voted 8-1 to retain the interest rate at -0.1 percent on current accounts that financial institutions maintain at the central bank. The bank will continue to […]

» Read more

$1 Trillion Task at BOE Is Daunting Ambition for Era of Bailey

Andrew Bailey is wagering that the Bank of England can eventually achieve a stimulus withdrawal that neither his predecessors nor his counterparts ever really dreamed was possible. Only 100 days in office this week, the new governor has already set out a daunting ambition reminiscent of the bold declarations of his predecessor, Mark Carney, by suggesting the institution should ultimately […]

» Read more

‘Profoundly disappointing’: KitKat cuts ties with Fairtrade

KitKat has severed its ties with Fairtrade, despite the organisation behind the scheme warning that thousands of farmers would be hit by the move. The boss of Fairtrade said Nestle’s decision to cut its 10-year association with the non-profit organisation was “profoundly disappointing”. The Swiss-owned food giant said it would now source its cocoa for KitKat bars from farms on […]

» Read more

FDA Nod For JAZZ’s Drug, BYSI’s PROTECTIVE-2 Trial Meets Goals, EDSA To Begin COVID-19 Drug Trial

Today’s Daily Dose brings you news about Momenta Pharma’s positive results from myasthenia gravis trial; BeyondSpring’s phase III trial results of Plinabulin in chemotherapy-induced neutropenia; Edesa’s progress in COVID-19 drug trial; FDA approval of Jazz Pharma’s Zepzelca and Celldex Therapeutics’ stock offering. Read on… 1. BeyondSpring’s PROTECTIVE-2 Trial Meets Goals BeyondSpring’s (BYSI) phase III trial evaluating drug candidate Plinabulin in […]

» Read more
1 170 171 172 173 174 210